Quantitative targeted proteomics for understanding the blood-brain barrier: Towards pharmacoproteomics

Expert Review of Proteomics

Volumn 11, Issue 3, 2014, Pages 303-313

  Ohtsuki, Sumio ^a   Hirayama, Mio ^a   Ito, Shingo ^a   Uchida, Yasuo ^b   Tachikawa, Masanori ^b   Terasaki, Tetsuya ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

absolute quantification; blood brain barrier; brain capillary endothelial cells; multiple reaction monitoring; pharmacoproteomics; quantitative targeted proteomics; transporter

Indexed keywords

ABC TRANSPORTER A6; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PROTEOME;

ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CLINICAL PHARMACOLOGY; DRUG DISTRIBUTION; DRUG PENETRATION; ELECTROPHORESIS; ENCEPHALITIS; ENERGY RESOURCE; GENE MUTATION; HUMAN; LIMIT OF QUANTITATION; MEMBRANE PERMEABILITY; METABOLITE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; OLIGODENDROGLIA; PHARMACOPROTEOMICS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SPECIES COMPARISON; SPECIES DIFFERENCE; TRANSCYTOSIS; ANIMAL; BRAIN; ENDOTHELIUM CELL; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; ENDOTHELIAL CELLS; HUMANS; P-GLYCOPROTEIN; PROTEOME; SPECIES SPECIFICITY;

EID: 84901056306     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.893830     Document Type: Review

References (62)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
2. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14
3. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32(11):1959-72
4. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007;24(9): 1745-58
5. Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24(9):1733-44
6. Braissant O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. J Inherit Metab Dis 2012;35(4):655-64
7. De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013: current state of the art. Seizure 2013;22(10):803-11
8. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci 2011;100(9): 3547-59
9. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 2011;339(2): 579-88
10. Uchida Y, Tachikawa M, Obuchi W, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 2013; 10(1):21
11. Boado RJ, Pardridge MM. A one-step procedure for isolation of poly(A)+ mRNA from isolated brain capillaries and endothelial cells in culture. J Neurochem 1991;57(6):2136-9
12. Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011;8(4):1332-41
13. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117(2): 333-45
14. Ohtsuki S, Yamaguchi H, Asashima T, Terasaki T. Establishing a method to isolate rat brain capillary endothelial cells by magnetic cell sorting and dominant mRNA expression of multidrug resistance-associated protein 1 and 4 in highly purified rat brain capillary endothelial cells. Pharm Res 2007;24(4):688-94
15. Ohtsuki S, Yamaguchi H, Katsukura Y, et al. mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting. J Neurochem 2008; 104(1):147-54
16. Lu Q, Murugesan N, Macdonald JA, et al. Analysis of mouse brain microvascular endothelium using immuno-laser capture microdissection coupled to a hybrid linear ion trap with Fourier transform-mass spectrometry proteomics platform. Electrophoresis 2008;29(12):2689-95
17. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008;107(6):1518-28
18. Warren MS, Zerangue N, Woodford K, et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009; 59(6):404-13
19. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP- glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 2012;40(1):83-92
20. Hoshi Y, Uchida Y, Tachikawa M, et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci 2013;102(9):3343-55
21. Ito K, Uchida Y, Ohtsuki S, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011; In press
22. Kamiie J, Ohtsuki S, Iwase R, et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 2008; 25(6):1469-83
23. Syvanen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009;37(3):635-43
24. Mori S, Ohtsuki S, Takanaga H, et al. Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 2004;90(4):931-41
25. Mori S, Takanaga H, Ohtsuki S, et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 2003; 23(4):432-40
26. Ohtsuki S, Kikkawa T, Mori S, et al. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther 2004;309(3):1273-81
27. van Gelder NM. Brain taurine content as a function of cerebral metabolic rate: osmotic regulation of glucose derived water production. Neurochem Res 1989;14(6): 495-7
28. Simpson IA, Dwyer D, Malide D, et al. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab 2008;295(2):E242-53
29. Meireles M, Martel F, Araujo J, et al. Characterization and modulation of glucose uptake in a human blood-brain barrier model. J Membr Biol 2013;246(9):669-77
30. Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000;879(1-2):115-21
31. Hawkins RA, Huang SC, Barrio JR, et al. Estimation of local cerebral protein synthesis rates with L-[1-11C]leucine and PET: methods, model, and results in animals and humans. J Cereb Blood Flow Metab 1989; 9(4):446-60
32. Young LT, Warsh JJ, Kish SJ, et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994;35(2):121-7
33. Irifune M, Fukuda T, Nomoto M, et al. Effects of ketamine on dopamine metabolism during anesthesia in discrete brain regions in mice: comparison with the effects during the recovery and subanesthetic phases. Brain Res 1997;763(2):281-4
34. Pardridge WM, Oldendorf WH. Transport of metabolic substrates through the blood-brain barrier. J Neurochem 1977; 28(1):5-12
35. Agarwal S, Uchida Y, Mittapalli RK, et al. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 2012;40(6):1164-9
36. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6(8):650-61
37. Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005;25(1):59-127
38. Ohtsuki S, Ikeda C, Uchida Y, et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm 2013;10(1): 289-96
39. Weksler BB, Subileau EA, Perriere N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19(13):1872-4
40. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30(4):1417-25
41. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010;31(6):246-54
42. Lippmann ES, Azarin SM, Kay JE, et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol 2012;30(8): 783-91
43. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012;11(6):O111-016717
44. Kito K, Ota K, Fujita T, Ito T. A synthetic protein approach toward accurate mass spectrometric quantification of component stoichiometry of multiprotein complexes. J Proteome Res 2007;6(2):792-800
45. Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008;106(4):1534-44
46. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24(9): 1759-71
47. Haqqani AS, Delaney CE, Tremblay TL, et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS 2013;10(1):4
48. Deracinois B, Duban-Deweer S, Pottiez G, et al. TNAP and EHD1 are over-expressed in bovine brain capillary endothelial cells after the re-induction of blood-brain barrier properties. PLoS One 2012;7(10):e48428
49. Chun HB, Scott M, Niessen S, et al. The proteome of mouse brain microvessel membranes and basal lamina. J Cereb Blood Flow Metab 2011;31(12):2267-81
50. Pottiez G, Deracinois B, Duban-Deweer S, et al. A large-scale electrophoresis-and chromatography-based determination of gene expression profiles in bovine brain capillary endothelial cells after the re-induction of blood-brain barrier properties. Proteome Sci 2010;8:57
51. Lu L, Yang PY, Rui Y, et al. Comparative proteome analysis of rat brain and coronary microvascular endothelial cells. Physiol Res 2007;56(2):159-68
52. Deracinois B, Pottiez G, Chafey P, et al. Glial-cell-mediated re-induction of the blood-brain barrier phenotype in brain capillary endothelial cells: a differential gel electrophoresis study. Proteomics 2013; 13(7):1185-99
53. Onodera H, Arito M, Sato T, et al. Novel effects of edaravone on human brain microvascular endothelial cells revealed by a proteomic approach. Brain Res 2013;1534: 87-94
54. Pottiez G, Duban-Deweer S, Deracinois B, et al. A differential proteomic approach identifies structural and functional components that contribute to the differentiation of brain capillary endothelial cells. J Proteomics 2011;75(2):628-41
55. Bergerat A, Decano J, Wu CJ, et al. Prestroke proteomic changes in cerebral microvessels in stroke-prone, transgenic [hCETP]-Hyperlipidemic, Dahl salt-sensitive hypertensive rats. Mol Med 2011;17(7-8):588-98
56. Ning M, Sarracino DA, Kho AT, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke 2011;42(1):37-43
57. Minagar A, Alexander JS, Kelley RE, et al. Proteomic analysis of human cerebral endothelial cells activated by glutamate/MK-801: significance in ischemic stroke injury. J Mol Neurosci 2009;38(2):182-92
58. Pottiez G, Sevin E, Cecchelli R, et al. Actin, gelsolin and filamin-A are dynamic actors in the cytoskeleton remodelling contributing to the blood brain barrier phenotype. Proteomics 2009;9(5):1207-19
59. Haqqani AS, Kelly J, Baumann E, et al. Protein markers of ischemic insult in brain endothelial cells identified using 2D gel electrophoresis and ICAT-based quantitative proteomics. J Proteome Res 2007;6(1): 226-39
60. Haseloff RF, Krause E, Bigl M, et al. Differential protein expression in brain capillary endothelial cells induced by hypoxia and posthypoxic reoxygenation. Proteomics 2006;6(6):1803-9
61. Franzén B, Duvefelt K, Jonsson C, et al. Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 2003;115(2):130-46
62. Ohtsuki S, Kamiya N, Hori S, Terasaki T. Vascular endothelium-selective gene induction by Tie2 promoter/enhancer in the brain and retina of a transgenic rat. Pharm Res 2005;22(6):852-7